Our findings emphasize the importance of integrating molecular and clinical assessments in PD and suggest that interventions aimed at enhancing SIRT1/Nrf2-mediated neuroprotection or reducing NLRP3-mediated inflammation may improve both symptom burden and quality of life. The gene discussed is SIRT1; the disease is Parkinson disease.